Johnson & Johnson (NYSE:JNJ – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a report issued on Friday, Benzinga reports. They currently have a $215.00 target price on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 44.02% from the stock’s current price.
Several other equities analysts have also recently weighed in on JNJ. Wells Fargo & Company decreased their price objective on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating for the company in a report on Thursday, August 31st. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 26th. JPMorgan Chase & Co. boosted their target price on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Morgan Stanley cut their price target on shares of Johnson & Johnson from $174.00 to $171.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 18th. Finally, HSBC assumed coverage on shares of Johnson & Johnson in a research note on Wednesday, September 6th. They set a “hold” rating and a $175.00 price objective on the stock. Eight equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $169.19.
Johnson & Johnson Stock Down 0.5 %
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.52 by $0.14. The company had revenue of $21.35 billion for the quarter, compared to the consensus estimate of $21 billion. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. As a group, analysts expect that Johnson & Johnson will post 10.1 EPS for the current fiscal year.
Institutional Trading of Johnson & Johnson
A number of institutional investors have recently modified their holdings of JNJ. Hibernia Wealth Partners LLC acquired a new stake in Johnson & Johnson in the third quarter valued at about $27,000. Atlantic Private Wealth LLC acquired a new position in Johnson & Johnson during the 1st quarter worth approximately $32,000. FNY Investment Advisers LLC bought a new position in Johnson & Johnson in the 3rd quarter valued at approximately $37,000. Tower View Wealth Management LLC boosted its position in Johnson & Johnson by 183.3% in the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 165 shares in the last quarter. Finally, Creative Capital Management Investments LLC grew its stake in shares of Johnson & Johnson by 43.0% during the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after buying an additional 86 shares during the last quarter. 68.40% of the stock is currently owned by institutional investors.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
- Five stocks we like better than Johnson & Johnson
- Best Stocks Under $10.00
- 3 large caps with red hot RSIs with upside
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Johnson Controls International: Nothing but upside for investors
- Do ETFs Pay Dividends? What You Need to Know
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.